Ya-Nan Jin
Overview
Explore the profile of Ya-Nan Jin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
258
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jin Y, Qiang M, Wang Y, Lin Y, Jiang R, Cao W, et al.
Cancer Immunol Immunother
. 2024 May;
73(7):125.
PMID: 38733402
Background: Despite the success of PD-1 blockade in recurrent/metastatic nasopharyngeal carcinoma (NPC), its effect for locoregionally advanced NPC (LANPC) remains unclear. This study aimed to evaluate the benefit of adding...
2.
Jin Y, Xiao Z, Yao W, Yu J, Zhang W, Marks T, et al.
Head Neck
. 2024 Feb;
46(8):2020-2030.
PMID: 38366693
Purpose: To evaluate the outcomes and toxicities of adding neoadjuvant chemotherapy (NAC) to concurrent chemoradiotherapy (CCRT) in elderly (≥65 years) patients with locoregionally advanced nasopharyngeal carcinoma (LANPC, stage III-IVa). Methods...
3.
Jin Y, Ruan Z, Cao W, Yang L, Yao W, Pei X, et al.
J Cancer Res Clin Oncol
. 2023 Jul;
149(13):11929-11940.
PMID: 37418058
Objectives: To compare neoadjuvant chemotherapy (NAC) plus concurrent chemoradiotherapy (CCRT) to CCRT alone in children and adolescents (age ≤ 18 years) with locoregionally advanced nasopharyngeal carcinoma (CA-LANPC, stage III-IVA). Materials...
4.
Yao J, Jin Y, Zhang W, Zhang H, Xia L
Radiother Oncol
. 2023 Feb;
181:109487.
PMID: 36736590
No abstract available.
5.
Yao J, Jin Y, Lin Y, Zhang W, Marks T, Ryan I, et al.
Radiother Oncol
. 2022 Nov;
178:109414.
PMID: 36375563
Background: To assess the feasibility of adjusting radiation dose (RD) in childhood NPC with favorable tumor response after neoadjuvant chemotherapy (NAC). Patients And Methods: Using an NPC-specific database, children and...
6.
He W, Wang L, Yin C, Yi J, Jin Y, Jiang C, et al.
Cancer Med
. 2022 Nov;
12(6):6488-6498.
PMID: 36373163
Background: Although the use of regorafenib plus nivolumab demonstrates promising outcomes in patients with refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC), this effect has not been substantiated in other...
7.
Jin Y, Xia T, Mai D, Yao J, Jiang C, He W, et al.
BMC Cancer
. 2022 May;
22(1):505.
PMID: 35524225
Background: We aim to investigate the prognostic value of weight loss during radiotherapy (RT) among patients with nasopharyngeal carcinoma (NPC). Methods: A total of 1149 NPC patients who received radical...
8.
Jin Y, Liu B, Peng K, Ou X, Zeng W, Zhang W, et al.
Head Neck
. 2022 Apr;
44(6):1404-1413.
PMID: 35373866
Background: To assess the prognostic value of the systemic inflammation response index (SIRI) combined with plasma load of Epstein-Barr virus (EBV) DNA in children and adolescents with locoregionally advanced nasopharyngeal...
9.
Jin Y, Yang Q, Li Z, Ou X, Zhang W, Marks T, et al.
Radiother Oncol
. 2021 Nov;
166:118-125.
PMID: 34838885
Purpose: To quantify and predict the survival benefits of cumulative cisplatin dose during concurrent chemoradiotherapy (CC-CCD) in children and adolescents with locoregionally advanced nasopharyngeal carcinoma (CA-LANPC). Materials And Methods: Patients...
10.
Jin Y, Qiang M, Liu M, Cheng Z, Zhang W, Ryan I, et al.
Cancer Cell Int
. 2021 Nov;
21(1):604.
PMID: 34772421
Background: We aimed to comprehensively investigate the optimal cumulative cisplatin dose during concurrent chemoradiotherapy (CC-CCD) for locoregionally advanced nasopharyngeal carcinoma (CA-LANPC) with different tumor responses after neoadjuvant chemotherapy (NAC). Methods:...